Immuneering’s atebimetinibin shows positive survival data in pancreatic cancer

Immuneering (IMRX) announced positive data from its ongoing Phase 2a clinical trial evaluating atebimetinib, an oral, once-daily novel MEK inhibitor, in combination with modified gemcitabine/nab-paclitaxel in first-line pancreatic cancer patients. 94% overall survival was observed at 6 months in first-line pancreatic cancer patients treated with atebimetinib + mGnP at the 320 mg once-daily dose of atebimetinib. The benchmark 6-month OS for the standard of care treatment in this population is 67%. The median OS was not yet reached at the data cutoff date. 72% progression-free survival was observed at 6 months in first-line pancreatic cancer patients treated with atebimetinib + mGnP at the 320 mg dose level. The median PFS was not yet reached at the data cutoff date. An overall response rate of 39% and a disease control rate of 81% were observed in response evaluable patients at both the 240 and 320 mg dose levels of atebimetinib + mGnP, including many patients with deepening, durable regressions and multiple examples of individual lesions rendered undetectable. Atebimetinib continued to demonstrate a markedly favorable tolerability profile in combination with mGnP. Based on these data, the company has increased target enrollment in the 1L pancreatic cancer atebimetinib + mGnP combination arm to approximately 50 patients. All results are reported using a data cutoff date of May 26. Immuneering is planning for several additional milestones related to atebimetinib, including: regulatory feedback on pivotal study plans in 4Q; data from additional patients in Phase 2a trial in 4Q; initiation of pivotal, randomized trial of atebimetinib in combination with mGnP in first-line pancreatic cancer in 2026. Initiation of additional atebimetinib clinical trial combination arms in 2026.